Literature DB >> 9819197

Biochemical, biophysical, and pharmacological characterization of bacterially expressed human agouti-related protein.

R D Rosenfeld1, L Zeni, A A Welcher, L O Narhi, C Hale, J Marasco, J Delaney, T Gleason, J S Philo, V Katta, J Hui, J Baumgartner, M Graham, K L Stark, W Karbon.   

Abstract

The agouti-related protein gene (Agrp) is a novel gene implicated in the control of feeding behavior. The hypothalamic expression of Agrp is regulated by leptin, and overexpression of Agrp in transgenic animals results in obesity and diabetes. By analogy with the known actions of agouti, these data suggest a role for the Agrp gene product in the regulation of melanocortin receptors expressed in the central nervous system. The availability of recombinant, highly purified protein is required to fully address this potential interaction. A nearly full-length form of AGRP (MKd5-AGRP) was expressed in the cytosolic or soluble fraction of Escherichia coli and appeared as large intermolecular disulfide-bonded aggregates. Following oxidation, refolding, and purification, this protein was soluble, and eluted as a single symmetric peak on RP-HPLC. Circular dichroism studies indicated that the purified protein contains primarily random coil and beta-sheet secondary structure. Sedimentation velocity studies at neutral pH demonstrated that MKd5-AGRP is monomeric at low micromolar concentrations. Mobility shifts observed using SDS-PAGE under reducing and nonreducing conditions for bacterially expressed and mammalian expressed AGRP were identical, an indication of a similar disulfide structure. The purification to homogeneity of a second, truncated form of AGRP (Md65-AGRP) which was expressed in the insoluble or inclusion body fraction is also described. Both forms act as competitive antagonists of alpha-melanocyte stimulating hormone (alpha-MSH) at melanocortin-3 (MC-3) and melanocortin-4 receptors (MC-4). The demonstration that AGRP is an endogenous antagonist with respect to these receptors is a unique mechanism within the central nervous system, and has important implications in the control of feeding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819197     DOI: 10.1021/bi981027m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  The melanocortin system and energy balance.

Authors:  Andrew A Butler
Journal:  Peptides       Date:  2006-01-23       Impact factor: 3.750

2.  Analytical ultracentrifugation as a contemporary biomolecular research tool.

Authors:  J L Cole; J C Hansen
Journal:  J Biomol Tech       Date:  1999-12

3.  Structural and molecular evolutionary analysis of Agouti and Agouti-related proteins.

Authors:  Pilgrim J Jackson; Nick R Douglas; Biaoxin Chai; Jonathan Binkley; Arend Sidow; Gregory S Barsh; Glenn L Millhauser
Journal:  Chem Biol       Date:  2006-12

Review 4.  Melanocortin-3 receptors and metabolic homeostasis.

Authors:  Karima Begriche; Clemencé Girardet; Patricia McDonald; Andrew A Butler
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 5.  The role of the Agouti-Related Protein in energy balance regulation.

Authors:  O Ilnytska; G Argyropoulos
Journal:  Cell Mol Life Sci       Date:  2008-09       Impact factor: 9.261

6.  Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice.

Authors:  Kavaljit H Chhabra; Donald A Morgan; Benjamin P Tooke; Jessica M Adams; Kamal Rahmouni; Malcolm J Low
Journal:  Mol Metab       Date:  2017-07-17       Impact factor: 7.422

7.  TET3 epigenetically controls feeding and stress response behaviors via AGRP neurons.

Authors:  Di Xie; Bernardo Stutz; Feng Li; Fan Chen; Haining Lv; Matija Sestan-Pesa; Jonatas Catarino; Jianlei Gu; Hongyu Zhao; Christopher E Stoddard; Gordon G Carmichael; Marya Shanabrough; Hugh S Taylor; Zhong-Wu Liu; Xiao-Bing Gao; Tamas L Horvath; Yingqun Huang
Journal:  J Clin Invest       Date:  2022-10-03       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.